8-K: Kura Oncology Unveils Robust Phase 1b Ziftomenib Data in Newly Diagnosed AML, Propelling Pivotal Phase 3 Trials

Kura Oncology, Inc. announced positive updated clinical data from its KOMET-007 Phase 1a/1b trial of ziftomenib in combination with standard chemotherapy for newly diagnosed acute myeloid leukemia, demonstrating high remission rates and supporting advancement to Phase 3 studies.

Summary

• Ziftomenib 600 mg QD combined with 7+3 demonstrated robust clinical activity in newly diagnosed NPM1-m and KMT2A-r AML patients in the KOMET-007 study.
• Among 71 response-evaluable patients, 92% (65/71) achieved a composite complete remission (CRc), with 93% for NPM1-m and 89% for KMT2A-r patients.
• Complete remission (CR) was achieved by 80% (57/71) of patients, specifically 84% for NPM1-m and 74% for KMT2A-r patients.
• High rates of CR minimal residual disease (MRD) negativity were observed: 71% for NPM1-m (median time to negativity 4.7 weeks) and 88% for KMT2A-r patients (median time to negativity 4.4 weeks).
• Ziftomenib did not delay time to neutrophil and platelet count recovery, which was comparable to intensive chemotherapy regimens.
• The safety profile was consistent with previously reported data, with common Grade 3 ziftomenib-related adverse events (TRAEs) including febrile neutropenia (15%), decreased platelet count (15%), anemia (11%), and decreased neutrophil count (11%).
• One case of Grade 3 differentiation syndrome (KMT2A-r) was successfully managed, and two cases of investigator-assessed QTc prolongation (KMT2A-r, Gr3) were reported, both in patients on other potentially QT-prolonging medications.
• No dose-limiting toxicities, drug-drug interactions, clinically meaningful ziftomenib-associated QTc prolongation, or additive myelosuppression were observed.
• 96% (47/49) of NPM1-m patients and 88% (29/33) of KMT2A-r patients remained alive and on study.
• Median duration of CR and median overall survival (OS) had not been reached for NPM1-m patients (median follow-up 24.9 weeks).
• For KMT2A-r patients, median duration of CR was 25.6 weeks (95% CI, 8.3-not evaluable), and median OS had not been reached (median follow-up 15.7 weeks).
• The company expects to start KOMET-017 intensive chemotherapy and non-intensive chemotherapy randomized Phase 3 studies in the second half of 2025.
• The New Drug Application (NDA) for ziftomenib based on positive results from the Phase 2 KOMET-001 trial (in R/R NPM1-m AML) was granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025.
• The collaboration with Kyowa Kirin Co., Ltd. funds the expansive AML development program through first-line U.S. commercialization.

Sentiment

Score: 9

Explanation: The document reports highly positive clinical trial data for ziftomenib, demonstrating robust efficacy and a manageable safety profile in a high-unmet-need indication. The clear path to pivotal Phase 3 trials and an upcoming PDUFA date for another indication, coupled with a strong financial position, indicates significant positive momentum and potential for the company.

Positives

• Robust clinical activity with high composite complete remission (CRc) rates of 92% overall (93% for NPM1-m, 89% for KMT2A-r) in newly diagnosed AML patients.
• Deep responses demonstrated by high complete remission (CR) rates of 80% overall and high CR minimal residual disease (MRD) negativity rates (71% for NPM1-m, 88% for KMT2A-r).
• Favorable safety profile consistent with previous reports, with no observed delay in neutrophil and platelet count recovery, and no additive myelosuppression.
• High patient survival rates, with 96% of NPM1-m and 88% of KMT2A-r patients remaining alive and on study.
• Median duration of CR and overall survival (OS) not yet reached for NPM1-m patients, indicating sustained benefit.
• Clear path to market with planned initiation of two pivotal Phase 3 studies (KOMET-017) in 2H 2025 for newly diagnosed AML.
• New Drug Application (NDA) for ziftomenib in relapsed/refractory NPM1-m AML granted Priority Review with a PDUFA target action date of November 30, 2025.
• Strong financial position with $703.2 million in cash, cash equivalents, and short-term investments as of March 31, 2025, including a $45 million milestone payment, anticipated to fund the AML program through potential commercialization.
• Strategic partnership with Kyowa Kirin Co., Ltd. provides funding for the extensive AML development program.
• Ziftomenib is potentially differentiated on safety and tolerability, combinability with intensive chemotherapy, strong CR rates, MRD negativity and durability, and convenience.

Negatives

• While generally well-tolerated, Grade 3 ziftomenib-related adverse events such as febrile neutropenia (15%), decreased platelet count (15%), anemia (11%), and decreased neutrophil count (11%) were observed in more than 10% of patients.
• Two cases of investigator-assessed Grade 3 QTc prolongation were reported, although attributed to concomitant medications.
• Median duration of CR for KMT2A-r patients was 25.6 weeks, which, while positive, is a defined median unlike the "not reached" status for NPM1-m patients.

Risks

• Compounds that appeared promising in early research or clinical trials may not demonstrate safety and/or efficacy in later preclinical studies or clinical trials.
• The Company may not obtain approval to market its product candidates.
• Uncertainties are associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies.
• Risks are associated with reliance on third parties to successfully conduct clinical trials.
• Risks are associated with reliance on outside financing to meet capital requirements (though current funding is stated as sufficient for the AML program).
• The collaboration with Kyowa Kirin may be unsuccessful.
• Unexpected adverse side effects or inadequate therapeutic efficacy of product candidates could delay or prevent regulatory approval or commercialization.
• Delays may occur in the commencement, enrollment, completion, or analysis of clinical testing, or in the reporting of data, or significant issues regarding the adequacy of clinical trial designs or execution may arise, leading to increased costs and delays or limiting regulatory approval.
• The U.S. Food and Drug Administration (FDA) may not agree with the Company's interpretation of data from clinical trials.
• The Company may decide, or the FDA may require, additional clinical trials or modifications to ongoing clinical trials.
• Additional risks and uncertainties may emerge from time to time.

Future Outlook

Kura Oncology expects to initiate two pivotal, independently powered, registration-enabling randomized Phase 3 studies (KOMET-017-IC and KOMET-017-NIC) in the second half of 2025, evaluating ziftomenib in combination with intensive and non-intensive chemotherapy for newly diagnosed NPM1-m or KMT2A-r AML. The New Drug Application (NDA) for ziftomenib in relapsed/refractory NPM1-m AML has a PDUFA target action date of November 30, 2025. The company also anticipates nominating a development candidate for its next-generation menin inhibitor program for diabetes by mid-2025 and expects additional clinical data readouts for KO-2806 and tipifarnib in solid tumors in 2H 2025.

Management Comments

• "Our goal is to develop transformative therapies to extend and improve the lives of patients with cancer."
• "We believe these data support the Phase 3 advancement of ziftomenib combination in newly diagnosed NPM1-m and KMT2A-r AML (KOMET-017)."
• "The 007 data looked good, especially the CR rate holding up for the KMT2Ar cohort."
• "We are embarking on a new era of menin inhibitors in combination with frontline therapy in newly diagnosed AML w/ NPM1m or KMT2Ar. impressed by the choice of CR MRD negativity as a primary endpoint in MEN-017."
• "Combination with standard of care is the way for menin inhibitors. Ziftomenib is potentially differentiated on safety and tolerability, combinability with intensive chemotherapy, strong CR rates, MRD negativity and durability, and convenience."
• "The safety profile really differentiates ziftomenib in terms of lack of QTc prolongation, CYP3A4 DDI and potentially less myelosuppression along with good time to count recovery. Ziftomenib demonstrates impressive CR and MRD negativity rates."

Industry Context

Acute Myeloid Leukemia (AML) represents a significant unmet medical need, with a 5-year survival rate of only 33% and up to 70% of patients relapsing within three years of achieving complete remission. Menin inhibitors, like ziftomenib, target the menin-KMT2A pathway, which is a foundational driver in up to 50% of AML cases, including those with NPM1-m and KMT2A-r mutations. This positions ziftomenib to address a large patient population within the AML landscape, with a potential annual U.S. market opportunity for menin inhibitors in first-line AML exceeding $7 billion. The focus on achieving minimal residual disease (MRD) negativity aligns with evolving industry standards, as published data suggest MRD negativity correlates better with long-term survival than morphologic complete remission alone.

Comparison to Industry Standards

• Time to neutrophil and platelet recovery with ziftomenib in combination with 7+3 was comparable to that observed with intensive chemotherapy regimens alone, as reported in studies by Lancet et al. (2018) and Erba et al. (2023).
• The high rates of complete remission (CR) and minimal residual disease (MRD) negativity observed with ziftomenib are highly competitive and potentially superior to current standard-of-care outcomes, particularly given the significant unmet need and high relapse rates in AML.
• The potential annual U.S. market opportunity for menin inhibitors in first-line AML is estimated to exceed $7 billion, indicating a substantial market for a differentiated therapy like ziftomenib.
• The company's strategy to establish CR MRD negativity as a primary endpoint in KOMET-017-IC aims to pave the way for a new surrogate endpoint in the field, reflecting a forward-thinking approach compared to traditional endpoints.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, clear regulatory pathway, and robust financial position, potentially leading to increased share price and long-term value.
• Patients: Significant positive impact as ziftomenib offers a promising new treatment option for newly diagnosed AML patients, particularly those with NPM1-m and KMT2A-r mutations, with high remission rates and deep molecular responses.
• Employees: Positive impact due to the company's strong progress and financial stability, potentially leading to job security and growth opportunities.
• Medical Community: Provides new insights and potential advancements in AML treatment, supporting further research and clinical practice.

Next Steps

• Initiate KOMET-017 intensive chemotherapy and non-intensive chemotherapy randomized Phase 3 studies in the second half of 2025.
• New Drug Application (NDA) for ziftomenib in R/R NPM1-m AML has a PDUFA target action date of November 30, 2025.
• Report topline results from KOMET-001 Phase 2 registration-directed trial in R/R NPM1-m AML.
• Receive FDA feedback on KOMET-017 registration-enabling protocol in 1L NPM1-m and KMT2A-r intensive and non-intensive AML.
• Initiate KOMET-015 Phase 1 trial of ziftomenib in combination with imatinib in patients with advanced GIST.
• Present preliminary clinical data from Phase 1b expansion of KOMET-007 in 1L non-intensive AML in 2H 2025.
• Initiate one or more expansion cohorts for KO-2806 in combination with cabozantinib in RCC in 2H 2025.
• Present preliminary clinical data from FIT-001 trial for KO-2806 as monotherapy and combo with cabozantinib in RCC in 2H 2025.
• Present clinical data from the KURRENT-HN trial of tipifarnib in combo with alpelisib in PIK3CA-dependent HNSCC in 2H 2025.
• Nominate a development candidate for next-generation menin inhibitor program for diabetes by mid-2025.

Key Dates

Recommendation

Keywords

Kura Oncology, ziftomenib, AML, Acute Myeloid Leukemia, menin inhibitor, NPM1-m, KMT2A-r, KOMET-007, KOMET-017, clinical trial, Phase 1b, Phase 3, complete remission, MRD negativity, oncology, hematology, biotechnology, pharmaceuticals, SEC filing, 8-K, Kyowa Kirin